 |
 
Renal Neoplasms: What the Nephrologist Should Know
Flash slide/audio
(ASN Renal Week Clinical Nephrology Conference Extract, November, 2008)
Bonsib: What are the basic types of renal neoplasms? What is their incidence, and what are the risk factors? What is the relationship between renal cysts and renal neoplasms? Which are the benign and malignant diffusely cystic renal neoplasms? What's the association between autosomal dominant polycystic kidney disease and renal cancer? What do nephrologists need to know about von Hippel-Lindau disease? Tuberous sclerosis? What's new in acquired cystic disease of CKD and transplant? When and how should these patients be screened? What are 2 new tumor types associated with this condition? Hudes: What are the latest data with regard to cytokine (interleukin-2 and interferon) therapy for renal cell carcinoma? What are the results with bevacizumab, sorafenib, sunitinib, temsirolimus, and everolimus? How does tumorigenesis progress and how might these new agents inhibit this process? How is the mTOR signalling pathway involved? What are the risks and adverse events with these newer therapies?
(more...)
|
Controversies in Anemia Management of Chronic Kidney Disease Patients
Flash slide/audio
(ASN Renal Week Official Symposium, October, 2009)
Agarwal: How does iron deficiency impact erythropoiesis and what are the causes of iron loss in ESRD patients? How is gut iron absorption regulated? How does one interpret the serum ferritin and TSAT in CKD? What are the risks of hemoglobin normalization? How does hepcidin regulate iron? Kalantar-Zadeh: How did the KDOQI anemia guidelines changes in 2006? In 2007? Where does transferrin come from? What are the normal values? How does TIBC associated with nutritional status? How does TIBC associate with survival in both cross-sectional and time-varying analyses? How dose TSAT associate with mortality. Is this different in predialysis patients? How is the platelet count related to TSAT? What is the structural pharmacology of ferritin? How is it related to malignancy, malnutrition, and CRP? What are the effects of ferritin on vascular calcification? What are the mortality implications of various ratios of TSAT/ferritin? At what level of ferritin and TSAT is ESA responsiveness the greatest?
(more...)
|
Racial Disparities in Patients with Chronic Kidney Disease
Flash slide/audio
(ASN Renal Week Official Symposium, October, 2009)
Boulware: How does the increased incidence of ESRD in Blacks compare to other ethnic groups, esp. Native Americans and Hispanics? What are the ethnic associations with albuminuria; with hypertension at various stages of CKD? How does the rate of CKD progression compare in Blacks vs. Caucasians? How does access to care and time of referral affect the ethnic effect on progression? How does ethnicity affect wait-listing for transplant, or likelihood of a living donor transplant? Sedor: How do we map genes to find gene-disease associations? What is the MALD technique? To what extent are race and genetics compatible concepts? How does MYH9 gene prevalence illustrate these concepts? Norris: How do environmental components contribute to racial disparities in CKD? How does psychological stress associate with oxidative stress? To what extent is air pollution involved; exposure to heavy metals; organic pollutants; smoking and substance abuse?
(more...)
|
Innovations in Caring for Patients with Hyponatremia
Flash slide/audio
(ASN Renal Week Official Symposium, October, 2009)
Rosner: How is hyponatremia related to morbidity, gait abnormalities, fractures and falls, and in-hospital mortality? Is resolution of hyponatremia associated with improved outcomes? Do management errors affect the prognosis? Sterns: In terms of management of hyponatremia, how much correction is enough? How much correction is too much? What do animal studies show us about chronic hyponatremia and myelinolysis? Is myelinolysis reversed by reintroduction of hyponatremia? What is the recommended therapy for acute water intoxication? What patients need to be treated acutely? What should be the therapeutic goal? What are the risk factors for osmotic demyelination syndrome?
Palmer: What are the various treatment strategies for chronic hyponatremia? What are the advantages and limitations of each? What are current indications for conivaptan and tolvaptan? What are potential benefits of treating hyponatremia in terms of risk of falls, quality of life, and cognition? How does CYP2D6 gene expression modulate hyponatremia due to antidepressants? How are polymorphisms of the TRPV4 gene involved? What causes the nephrogenic syndrome of inappropriate diuresis? What are results of vasopressin antagonists in congenital nephrogenic DI, in Meniere's disease? What are potential future uses of V2R antagonists?
(more...)
|
 |
 |
 |
ANNA CE
(Article Free, $CE) |
ANNA CE (NNJ)
Target audience: Nurses. Article free, CE requires payment to
ANNA
via HDCN.
Pictures and Perspectives: A Unique Reflection on Interdialytic Weight Gain
(Vol 36/No. 6. Expires 12/20/2011)
Peter M. Sinclair, RN, and Vicki Parker, PhD, RN
1.1 hr
A Qualitative Analysis of Patient Reported Symptoms of Anemia
(Vol 36/No. 6. Expires 12/20/2011)
Kathryn F. Lasch, PhD, Christopher J. Evans, PhD, and Dori Schatell, MS
1.1 hr
Lethality of Endocarditis Due To S. Aureus among Patients On Hemodialysis
(Vol 36/No. 6. Expires 12/20/2011)
Cibele Grothe, MSc, Angélica Belasco, PhD, Ana Bettencourt, PhD, Solange Diccini, PhD, Lucila Vianna, PhD, Antonio Pignatari, MD, Ricardo Sesso, MD, and Dulce Barbosa, PhD
1.4 hr
African-American Women’s Perceived Health Status While Caring for a Relative with End Stage Renal Disease
(Vol 36/No. 6. Expires 12/20/2011)
Dina J. Byers, PhD, ARNP, CNS-C, Tamara Harris Beard, PhD, FNP, and Mona N. Wicks, PhD, RN
1.4 hr
|
|
|
 |
Annual Dialysis Conference 2009
now in MP3
|
AUDIOFILE
LIST (Annual Dialysis Conference 2009)
(14 talks)
Home Hemodialysis
Christopher R. Blagg, MD, Michael Aragon, MD, Sylvia Donato-Moore, BSN, RN, CNN, Michelle Carver, BSN, RN,CNN, Dorian Schatell, MS, Linda Upchurch, BS, MBA, and Joel Glickman, MD
Elderly PD Patients
Allen Nissenson, MD, Dimitrios Oreopoulos, MD, Matthew Oliver, MD, and Allen Nissenson, MD
Dialysis Technology: Present and Future
Andrew Davenport, MD; James Winchester, MD; and Ingrid Ledebo, PhD
|
 |
|
|
|
Hypertension, Cardiovascular:
None this update.
Dialysis, CKD:
Contrast dye for fistulography and Kru; Vibrating the dialyzer enhances Kd; Reticulocytosis and EPO resistance; New citrate anticoagulation device; Self-reported urine output in ESRD; ECF volume and mortality; Dialysate K and cardiac arrest; Need to calibrate dialysate Na; Bioimpedance vs. reference methods; 3-hr 6/week dialysis benefits long-term; Scottish nephrologists' preferences for dialysis; Dextrose load due to ACD-A in citrate anticoagulation; pre- vs. postdilution CVVH; Nafamostat mesilate for CVVH; Removing AGEs; Predialysis hyponatremia and mortality; CV events in AURORA; Abdominal aorta calcification bad; Abdominal obesity, glycosylated Hb, CRP, and outcomes; Higher dialysis doses in Japanese women good; Strategies to increase influenza vaccination; Waist-to-hip in PD; Interferon/ribavirin in ESRD; Hb protocols, Hb sampling, use of postdialysis Hb; rHuEPO dosing errors due to concentrated vials; RBC lifespan and inflammation; 25-D levels and ESA resistance; Hepcidin and response to IV iron;
GLA protein and calcification; CaC03 vs. Ca acetate; Ferric citrate as a Pi binder; Empirical treatment of tuberculosis; Calcification index and mortality; LDL particle size; Intracranial carotid artery calcification and stroke risk; Ethnicity and hemorrhagic stroke; Bilateral symmetry in uremic itching.
Clinical Nephrology:
Smoking and cystatin GFR; Cystatin C assays compared; Cystatin C vs. creatinine; Low incidence of RCC in ADPKD.
(more...)
|
|
 |
|
|
The role of the mammalian target of rapamycin (mTOR) in renal disease
Lieberthal and Levine review how mTOR is involved in recovery from renal injury, diabetic nephropathy, cystic diseases of the kidney, and renal carcinoma;
in the December issue of the J Am Soc Nephrol (CJASN)
(more...) |
|
|
Cardiorenal syndrome in acute decompensated heart failure
Sarraf, Maoumi and Schrier review pathogenesis and various possible treatments,
in the December issue of the Clinical J Am Soc Nephrol (CJASN)
(more...) |
|
|
Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease: a review of the evidence
Thomas and Jaber look critically at the data for use of hemodiafiltration and other convective therapies in both acute and chronic situations;
in the Nov/Dec issue of Seminars in Dialysis.
(more...) |
|
|
Interstitial cystitis: an unsolved enigma
Moutzouris and Falagas review the diagnosis of IC, the role of specific and supportive therapies, and directions for future research,
in the November issue of the Clinical J Am Soc Nephrol (CJASN)
(more...) |
|
|
MASTering Treg function to promote tolerance
Levings and Thomson discuss a paper by Noelle in which rejection of skin grafts was treated by activation of mast cells in a T-cell mediated process;
in the October issue of the Am J Transplant.
(more...) |
|
|
The Declaration of Istanbul: Review and commentary by the American Society of Transplant Surgeons Ethics Committee and Executive Committee
Reed et al talk about the issues in applying the principles in this declaration to the North American setting;
in the November issue of the Am J Transplant.
(more...) |
|
|
Encapsulating peritoneal sclerosis: Importance to the hemodialysis practitioner
In this Trainee Forum, Perl, Bargman and Chan tell us why peritoneal sclerosis is such an important issue to long-term PD and what we can do about it;
in the October 2009 issue of the Hemodial Int
(more...) |
|
|
Mineralocorticoid receptor blockers and chronic kidney disease
Jain and colleagues review the scientific basis for renoprotection by blocking mineralocorticoid receptors, including a discussion of risks and benefits of current treatments;
in the October issue of the Clinical J Am Soc Nephrol (CJASN)
(more...) |
|
Salt intake and stroke
96